EBUS-TNBA 22G samples: Comparison of PD-L1 expression between DAKO and BIOCARE^®

Abstract

Introduction: Lung cancer is diagnosed at advanced stage due to lack of early disease symptoms. Currently we have several different biopsy techniques such as; radial endobronchial ultrasound, convex probe endobronchial ultrasound, electromagnetic navigation, ct guided biospy and transthoracic ultrasound biopsy. Novel therapies such as; immunotherapy is being used for non-small cell lung cancer in the everyday clinical practice as first and second line treatment. Programmed ligand-1 is essential in order to administer immunotherapy as first line treatment. Patients and Methods: Two thousands and two patients were included in our study where programmed ligand 1 was evaluated with DAKO technique and BIOCARE ®. Cell blocks were obtain with convex probe ebus-tbna 22G needle. Results: The Deming regression between DAKO and BIOCARE clone revealed an amazingly strong linear relationship as the coefficient of determination indicated (R 2 =0.999) and the variance ratio close to 1 (0.978), proving that both techniques can equally well be substituted for each other. The regression coefficient equals to 1 and the intercept hardly differs from 0 (0.936). In practice, this relationship permits adopting the economically affordable BIOCARE clone for further medical considerations. Conclusion: No statistical difference was observed between DAKO and BIOCARE ® , therefore we propose that both techniques can be used in order to investigate the expression of programmed ligand 1 with safety. PD-L1 expression was higher in the central mass instead of the lymphnodes.

Lung cancer biopsies: Comparison between simple 22G, 22G upgraded and 21G needle for EBUS-TBNA

“…Endobronchial ultrasound with convex probe and PET-CT combined provide in several lung cancer cases the staging of the disease. In advanced stage disease molecular biomarkers such epidermal growth factor (EGFR), anaplastic lymphoma kinase (ALK), proto-oncogene B-Raf (BRAF), proto-oncogene tyrosine-protein kinase (ROS1) and programmed death-ligand 1 (PD-L1), provide us with useful information regarding the treatment of the patient 8 - 11 . PD-L1 can be efficiently assessed with cell-blocks 11 - 13 .…”

Intratumoral Treatment with Chemotherapy and Immunotherapy for NSCLC with EBUS-TBNA 19G

“…Moreover; the issue method of administration, should be easy for the patient and without complication. EBUS-TBNA is a safe method under mild anesthesia and with small needles that do not cause any serious adverse effects 4 , 5 , 40 , 41 . We had to carefully choose which patients would benefit from this treatment modality and these patients would be two groups with endobronchial lesions and large parenchymal masses.…”

Examination of Endobronchial Ultrasound-guided Transbronchial Needle Aspiration Using a Puncture Needle With a Side Trap

“…The incidence of complications after EBUS-TBNA has been reported to be 0.15% to 0.46% 18,19 , and EchoTip ProCore® was safe as it did not increase the incidence of complications. Furthermore, several studies have reported that samples obtained using EBUS-TBNA as a cell block can allow PD-L1 staining 20,21 . The present study shows that EBUS-TBNA with EchoTip ProCore® can consistently yield large tissues suitable for direct immunostaining of PD-L1 (Figure 3).…”